203 related articles for article (PubMed ID: 35132075)
1. CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy.
Salgado-Albarrán M; Späth J; González-Barrios R; Baumbach J; Soto-Reyes E
NPJ Syst Biol Appl; 2022 Feb; 8(1):5. PubMed ID: 35132075
[TBL] [Abstract][Full Text] [Related]
2.
Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
[TBL] [Abstract][Full Text] [Related]
3. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
[TBL] [Abstract][Full Text] [Related]
4. The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer.
Salgado-Albarrán M; González-Barrios R; Guerra-Calderas L; Alcaraz N; Estefanía Sánchez-Correa T; Castro-Hernández C; Sánchez-Pérez Y; Aréchaga-Ocampo E; García-Carrancá A; Cantú de León D; Herrera LA; Baumbach J; Soto-Reyes E
Oncogenesis; 2019 Aug; 8(8):41. PubMed ID: 31406110
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.
Garikapati KR; Patel N; Makani VKK; Cilamkoti P; Bhadra U; Bhadra MP
Biochem Biophys Res Commun; 2017 Feb; 484(1):93-99. PubMed ID: 28104398
[TBL] [Abstract][Full Text] [Related]
6. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
Itamochi H; Oishi T; Oumi N; Takeuchi S; Yoshihara K; Mikami M; Yaegashi N; Terao Y; Takehara K; Ushijima K; Watari H; Aoki D; Kimura T; Nakamura T; Yokoyama Y; Kigawa J; Sugiyama T
Br J Cancer; 2017 Aug; 117(5):717-724. PubMed ID: 28728166
[TBL] [Abstract][Full Text] [Related]
7. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
Huang J; Zhang L; Greshock J; Colligon TA; Wang Y; Ward R; Katsaros D; Lassus H; Butzow R; Godwin AK; Testa JR; Nathanson KL; Gimotty PA; Coukos G; Weber BL; Degenhardt Y
Genes Chromosomes Cancer; 2011 Aug; 50(8):606-18. PubMed ID: 21563232
[TBL] [Abstract][Full Text] [Related]
8. Targeting CTCFL/BORIS for the immunotherapy of cancer.
Loukinov D
Cancer Immunol Immunother; 2018 Dec; 67(12):1955-1965. PubMed ID: 30390146
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
10. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
11. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
Link PA; Zhang W; Odunsi K; Karpf AR
Cancer Immun; 2013; 13():6. PubMed ID: 23390377
[TBL] [Abstract][Full Text] [Related]
12. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
13. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
14. Expression of the CTCFL Gene during Mouse Embryogenesis Causes Growth Retardation, Postnatal Lethality, and Dysregulation of the Transforming Growth Factor β Pathway.
Sati L; Zeiss C; Yekkala K; Demir R; McGrath J
Mol Cell Biol; 2015 Oct; 35(19):3436-45. PubMed ID: 26169830
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
[TBL] [Abstract][Full Text] [Related]
16. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.
Gasparri ML; Besharat ZM; Farooqi AA; Khalid S; Taghavi K; Besharat RA; Sabato C; Papadia A; Panici PB; Mueller MD; Ferretti E
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2313-2318. PubMed ID: 30109500
[TBL] [Abstract][Full Text] [Related]
17. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.
Dobbin ZC; Landen CN
Int J Mol Sci; 2013 Apr; 14(4):8213-27. PubMed ID: 23591839
[TBL] [Abstract][Full Text] [Related]
18. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.
Kannan K; Coarfa C; Chao PW; Luo L; Wang Y; Brinegar AE; Hawkins SM; Milosavljevic A; Matzuk MM; Yen L
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1272-7. PubMed ID: 25733895
[TBL] [Abstract][Full Text] [Related]
19. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Li H; Zeng J; Shen K
Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
[TBL] [Abstract][Full Text] [Related]
20. PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.
Rausio H; Cervera A; Heuser VD; West G; Oikkonen J; Pianfetti E; Lovino M; Ficarra E; Taimen P; Hynninen J; Lehtonen R; Hautaniemi S; Carpén O; Huhtinen K
Neoplasia; 2024 May; 51():100987. PubMed ID: 38489912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
